Redeye: Embracer Group - Transformative licensing deal saves the day

2023-02-17 08:54:00

Redeye updates its view on Embracer post its Q3 report, which showed solid net sales but weaker profitability. However, Embracer reiterated its guidance for FY 2022/2023e-2023/2024e.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.